Thu, Jul 24, 2014, 9:14 AM EDT - U.S. Markets open in 16 mins.


% | $
Click the to save as a favorite.

Insmed Incorporated Message Board

  • jsblvbjb jsblvbjb Jul 4, 2013 1:11 PM Flag

    Happy Independence Day!!!

    With the extra time today, I studied the results from the phase 3 study slides. Well, having been an excellent students of statistics, the results really impressed me. Even after Tobi raced out of the gate with a comfortable lead, Arikace consistently caught up to practically dead even, proving sustained efficacy that matched the phase 2 results. Tobi is not a bad antibiotic as many have portrayed it, but Arikace achieved sustained efficacy with good safety with a far great ease of use (once daily vs. twice). This is why I initially stated that Arikace kicked Tobi's butt. As for the minutia that some health experts are tripping over, it's the achievement of non-inferiority that really counts. Doctors vouched for the viablity and efficicacy on the conference call, which I listened to live. Every analyst is on board and there will be more to come. Folks, we have a winner!!!
    God bless the USA!

    Sentiment: Strong Buy

18.12Jul 23 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
General Motors Company
NYSEWed, Jul 23, 2014 4:01 PM EDT
Facebook, Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT